The DOI matches its Crossref record; 204 of the 216 references it cites were found in a registry or an index.
GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms
Open accessAbstract
Cardiovascular outcome trials (CVOTs) in people living with type 2 diabetes mellitus and obesity have confirmed the cardiovascular benefits of glucagon-like peptide 1 receptor agonists (GLP-1RAs), including reduced cardiovascular mortality, lower rates of myocardial infarction, and lower rates of stroke. The cardiovascular benefits observed following GLP-1RA treatment could be secondary to improvements in glycemia, blood pressure, postprandial lipidemia, and inflammation. Yet, the GLP-1R is also expressed in the heart and vasculature, suggesting that GLP-1R agonism may impact the cardiovascular system. The emergence of GLP-1RAs combined with glucose-dependent insulinotropic polypeptide and glucagon receptor agonists has shown promising results as new weight loss medications. Dual-agonist and tri-agonist therapies have demonstrated superior outcomes in weight loss, lowered blood sugar and lipid levels, restoration of tissue function, and enhancement of overall substrate metabolism compared to using GLP-1R agonists alone. However, the precise mechanisms underlying their cardiovascular benefits remain to be fully elucidated. This review aims to summarize the findings from CVOTs of GLP-1RAs, explore the latest data on dual and tri-agonist therapies, and delve into potential mechanisms contributing to their cardioprotective effects. It also addresses current gaps in understanding and areas for further research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, emerging reviews highlight the absence of cardiovascularoutcomes data and the necessity to evaluate pancreatic, hepatic, and cardiometabolic safety under prolonged GLP-1/GIP/GCGR stimulation before establishing retatrutide as a long-term therapeutic standard.46”
From The Triple‐Agonist Revolution: Retatrutide and the Paradigm Shift in Multi‐Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities (2026) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, GLP-1 receptor agonists and tirzepatide improve multiple cardiometabolic pathways, including glycaemic control, blood pressure, inflammation, endothelial function, insulin sensitivity, and renal physiology, suggesting that both weight-loss-dependent and weight-loss-independent mechanisms likely contribute to their CV effects.[16][17][18]”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In individuals with T2D, CV, and HF benefits associated with incretin-based therapies are likely mediated only partly by intentional weight loss.”
From Outcomes in patients with diabetes, atherosclerotic cardiovascular disease, and heart failure treated with tirzepatide or dulaglutide: SURPASS-CVOT analysis (2026) · cites this paper as [17]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
International Journal of Molecular Sciences
(2024) · International Journal of Molecular Sciences · doi:10.3390/ijms · Cited by 10,111
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Biochemical and Biophysical Research Communications
(1960) · Nature · doi:10.1038/186124d0 · Cited by 6,700
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
HOSKINS, R. G. (1953) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-13-4-473 · Cited by 3,780
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Cited by
Sattar, N. A., & Lee, M. M. Y. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00363-2 · Cited by 57
Shah, E., Al-Shiab, R., Abdo, A., Özbek, L., Covic, A. C., & Kanbay, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70713 · Cited by 17
Pereira, D. E., Tummala, S., Mittal, M. M., Obey, M. R., Berkes, M. B., McAndrew, C. M., & Wilson, J. L. (2025) · Injury · doi:10.1016/j.injury.2025.112746 · Cited by 15
Papaetis, G. S., Picolos, M. K., & Sacharidou, A. (2025) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/202298 · Cited by 14
“The administration of GLP-1R agonists in patients with T2D has achieved significantly lower hemoglobin A 1C (A 1C ) levels and promoted remarkable weight loss and significant cardiometabolic improvements [66].”
Zhou, Y., Tu, L., Wang, X., Xu, J., Xu, S., Ning, X., Xiong, X., & Zheng, N. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01399 · Cited by 10
Metadata
- Authors
- Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E.
- Affiliations
- University of Ottawa (CA)
- Ottawa Heart Institute (CA)
- Venue
- Journal of Endocrinology
- Publisher
- Bioscientifica
- Published
- 2024-08-15
- Volume
- 263
- Issue
- 1
- ISSN
- 0022-0795 (ISSN-L)
- 1479-6805
- PMC
- PMC11466209
- OpenAlex
- W4401614784
- Semantic Scholar
- e704e36cb68ed5cba32d62ed23dd80a70996416a
- Cited by
- 51
- References
- 216
- Citations by year
- 2026: 36 · 2025: 15
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, cardiovascular risk, cardioprotection, type 2 diabetes, obesity, cardiovascular outcome trials, GIP/GLP-1 dual agonist, anti-obesity drugs, myocardial infarction, stroke, glycemia, blood pressure, postprandial lipemia, inflammation
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Heart Disease Risk Factors, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. https://app.cochat.ai/papers/10.1530/joe-24-0046
- The paper
- Mullur, N., Morissette, A., Morrow, N. M., & Mulvihill, E. E. (2024). GLP-1 receptor agonist-based therapies and cardiovascular risk: a review of mechanisms. Journal of Endocrinology. https://doi.org/10.1530/joe-24-0046
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.